Delivery Order SPE2DB20D1109-SPE2DB25FP70R
- Not listed
- The Defense Logistics Agency awarded a $4,687.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen auto-injectors on August 28, 2025, with a completion date of September 19, 2025. This non-set-aside competitive award is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a standard...
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pens on August 14, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract does not utilize a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE (tezepelumab) is a biologic treatment for moderate-to-severe asthma, representing a specialized...
- The Defense Logistics Agency awarded a delivery order valued at $46,871.80 to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injectors, with performance through September 16, 2025. This non-competitive, firm fixed-price delivery order was issued on August 25, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. TEZSPIRE is a biologic medication indicated for moderate-to-severe eosinophilic asthma, representing a specialized pharmaceutical product...
- The Defense Logistics Agency awarded a $2,343.59 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen auto-injectors, with an ultimate completion date of August 25, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award issued on August 4, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE (tezepelumab) is a biologic medication used for the treatment of severe asthma,...
- The Defense Logistics Agency (DLA) awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of August 11, 2025. This non-set-aside contract was competitively awarded on July 21, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE is a specialty biologic medication used in the treatment of moderate-to-severe asthma, reflecting DLA's ongoing...
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 ml pen auto-injectors on September 3, 2025, with an ultimate completion date of September 24, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors. This competitive award, issued on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price transaction under a non-set-aside procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of TEZSPIRE 210 mg/1.91 ml auto-injector pens valued at $4,687.18. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The contract requires completion by September 3, 2025, with performance taking place at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP70RDelivery Order
The Defense Logistics Agency awarded a competitive delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injectors, with a completion date of September 29, 2025. This non-set-aside order was issued on September 8, 2025, under firm fixed-price terms and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. TEZSPIRE (tezepelumab) is a monoclonal antibody biologic used to treat severe asthma, representing a specialized pharmaceutical product within the broader medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen maintains extensive experience fulfilling DLA requirements across multiple therapeutic domains, including specialty medications, biologics, and medical devices for military healthcare programs. The company's competitively awarded contracts with DLA demonstrate its capability to supply specialized pharmaceuticals at scale to support Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 9/8/25 |